FDA requests additional data on Novartis quadrivalent meningococcal conjugate vaccine, Menveo®
13 February 2012 | By Novartis
Novartis has received a Complete Response letter from the US FDA...
List view / Grid view
13 February 2012 | By Novartis
Novartis has received a Complete Response letter from the US FDA...
6 February 2012 | By Chamberlain Healthcare PR
The European Commission has approved the use of Galvus® (vildagliptin)...
1 February 2012 | By Novartis
The US Food and Drug Administration has approved an update to the Glivec® (imatinib)* label...
30 January 2012 | By Novartis
Novartis is a part of an international effort to eliminate or control 10 NTDs by the end of the decade...
20 January 2012 | By Novartis
Update of the Glivec® (imatinib)* label...
19 January 2012 | By Novartis
Sandoz announced that it has initiated two milestone Phase III clinical trials...
18 January 2012 | By Novartis
Novartis has received regulatory approval in China from the SFDA for Lucentis® (ranibizumab)...
13 January 2012 | By Novartis
US General Medicines restructuring results in reduction of 1,960 positions...
8 January 2012 | By Novartis
There have been no related adverse events reported with the issues leading to the recall...
15 December 2011 | By Novartis
Once-daily oral MS medicine showed a 48% relative reduction in annualized relapse rate, meeting primary endpoint in Phase III placebo-controlled study...
13 December 2011 | By Novartis
Results from two pivotal Phase III trials...
8 December 2011 | By Novartis
Updated results of a Phase III study...
5 December 2011 | By Novartis
The European Commission has approved Galvus® (vildagliptin) (50 mg once a day) for the treatment of type 2 diabetes patients with moderate or severe renal impairment...
2 December 2011 | By Novartis
Novartis will showcase more than 160 presentations on data from its robust oncology portfolio...
28 November 2011 | By Novartis
Rasitrio®, the first triple combination of aliskiren, amlodipine and hydrochlorothiazide in a single pill has received approval...